Cell & Gene Therapy Clinical Trial Services Market – By Service (Clinical Trial Design & Planning), Phase, Indication, Therapy Type (Gene, Cell, Gene Modified Cell Therapy), End-use (Pharmaceutical & Biotechnology, CRO) – Global Forecast (2024 ­ 2032)

Cell and Gene Therapy Clinical Trial Services Market Size

Cell And Gene Therapy Clinical Trial Services Market size was valued at USD 4 billion in 2023 growing at a CAGR of 10.8% between 2024 and 2032, driven by factors such as the growing prevalence of chronic and genetic diseases that have created a strong demand for innovative treatment options like cell and gene therapies, leading to a greater number of clinical trials being conducted.
 

Moreover, the ongoing advancement in the field of biotechnology and gene editing technologies have significantly increased the efficiency and effectiveness of cell and gene therapies, that leads to a greater number of companies investing in clinical trials to test new treatments, thus, driving the market growth. For instance, in November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.
 

Under the terms of the collaboration agreement, AstraZeneca leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design novel cell and gene therapy products, strengthening AstraZeneca’s growing offering in this space. Therefore, this increase in the number of research & development activities in the field of gene editing will increase the demand for clinical trials services that propel the growth of the market.
 

The cell and gene therapy clinical trial services market refers to the sector within the healthcare industry that provides services specifically tailored to support clinical trials for cell therapy and gene therapy treatments. Clinical trials are essential for testing the safety and efficacy of new cell and gene therapy treatments before they can be approved for widespread clinical use. Companies specializing in cell and gene therapy clinical trial services offer a range of services including patient recruitment, study design, regulatory compliance, manufacturing support, data management, and monitoring to facilitate the successful execution of these trials.
 

Cell and Gene Therapy Clinical Trial Services Market Trends

The rapid pace of technological advancement in cell and gene therapy is a catalyst for the growth of the market. These advancements not only enhance the efficacy of treatments but also expand the therapeutic applications of cell and gene therapy across a wide range of diseases that is anticipated to boost the growth of the market.
 

• For instance, in April 2022, Labcorp a leading global life sciences company collaborated with Xcell Biosciences, Inc, a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market. Through this collaboration, LabCorp and Xcellbio work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). Thus, the demand for high-quality clinical trial services is expected to grow in tandem, ensuring the safe and effective translation of these innovative therapies from the laboratory to the hospitals & clinic, is anticipated to boost the growth of the market.
   

Cell and Gene Therapy Clinical Trial Service Market Analysis

Based on the service, the global market is classified into clinical trial design and planning, supply & logistic services, regulatory affairs & compliance, data management & biostatics, site management & monitoring, and other services. The regulatory affairs & compliance segment dominated the market with revenue of USD 997.7 million in 2023.
 

• Regulatory compliance is essential to demonstrate the safety and efficacy of these therapies in clinical trials. Robust regulatory affairs practices help ensure that appropriate safety measures are implemented and followed throughout the development process.
   
• Moreover, regulatory service providers offer expertise in global regulatory strategy development, submission management, and interactions with regulatory agencies, facilitating the expansion of cell and gene therapy trials into new markets, thereby augmenting the service market growth.

Based on the phase, the cell and gene therapy clinical trial service market is classified into phase I, phase II, phase III, and phase IV. The phase II segment dominated the market with market share of 35.2% in 2023.
 

• Phase II trials typically involve larger patient populations than phase I trials, requiring efficient patient recruitment and retention strategies. Advances in patient engagement, site selection, and recruitment technologies contribute to the successful execution of phase II trials.
   
• Moreover, phase II trials typically focus on disease-specific endpoints relevant to the targeted indication, such as tumour response rates, progression-free survival, or improvements in disease symptoms. These endpoints provide meaningful clinical data on the therapeutic efficacy of cell and gene therapies in treating the targeted disease. As sponsors seek to demonstrate meaningful clinical outcomes in phase II trials, there is a demand for specialized expertise in study design, endpoint selection, and data analysis within the clinical trial services market.
   

Based on the indication, the global cell and gene therapy clinical trial service market is classified into oncology, hematology, endocrine/metabolic disorders, infectious diseases, neurology, cardiovascular diseases, musculoskeletal disorders, and other indications. The oncology segment is expected to exhibit CAGR of 11.1% during the analysis period.
 

• Cell and gene therapies offer promising new approaches for treating cancer by targeting specific molecular pathways, enhancing the body's immune response against tumours, or directly killing cancer cells. The urgency to address the unmet needs in oncology fuels a strong demand for clinical trial services to develop and evaluate innovative cell and gene therapy treatments.
   
• Moreover, cell and gene therapies offer the potential for highly targeted and personalized treatments based on a patient's unique tumour biology. Biomarker-driven clinical trials aim to identify patient subpopulations most likely to benefit from specific therapies, facilitating more efficient drug development and improving patient outcomes. Thus, the clinical trial services that support biomarker identification, patient stratification, and companion diagnostic development which are essential for advancing personalized oncology therapies, will spur the market growth.
   

Based on the therapy type, the global cell and gene therapy clinical trial services market is classified into gene therapy, cell therapy, and gene modified cell therapy. The cell therapy segment is expected to reach USD 4.2 billion by end of 2032.
 

• Improvements in cell manufacturing techniques, such as automation and scale-up capabilities, reduce production costs and increase the scalability of cell therapies is the major factors that propel the growth of the market.
   
• Additionally, innovations in delivery systems enhances the efficiency and safety of administering cell therapies. This will lead to growing volume of data generated in clinical trials necessitates sophisticated data management and analysis capabilities, further driving the demand for specialized services.
   

Based on end-use, the cell and gene therapy clinical trial services market is classified into pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end-users. The pharmaceutical & biotechnology companies’ segment accounted for USD 1.7 billion growing at 11.1% CAGR between 2024 – 2032 period.
 

• Pharmaceutical and biotechnology companies are heavily investing in the research and development of cell and gene therapies due to their potential to address unmet medical needs across a wide range of diseases. The growing understanding of cellular and genetic mechanisms underlying diseases, coupled with advancements in technology, has fueled interest and investment in developing novel cell and gene therapy products. As these companies advance therapies through preclinical and clinical development stages, there is a corresponding increase in demand for specialized clinical trial services to support the research efforts.
   
• Moreover, pharmaceutical and biotechnology companies often form strategic partnerships and collaborations with contract research organizations (CROs), academic institutions, and other stakeholders to advance their cell and gene therapy programs. Clinical trial service providers play a key role in these collaborations by offering specialized services tailored to the unique needs of cell and gene therapy programs, thereby driving growth in the pharmaceutical and biotechnology companies’ segment.

The cell and gene therapy clinical trial service market in U.S. is expected to exhibit 11% CAGR between 2024 - 2032.
 

• The presence of robust biopharmaceutical industry with numerous pharmaceutical and biotechnology companies actively engaged in cell and gene therapies research and development activities in North America coupled with substantial investment in innovative technologies and therapies, drives the demand for cell and gene therapy clinical trial services in this region.
   
• Moreover, the growing burden of chronic and genetic diseases, coupled with the limitations of existing treatment modalities, underscores the need for innovative therapies to address unmet medical needs. Therefore, cell and gene therapies offer promising new approaches for treating these conditions, driving the demand for clinical trials to evaluate their safety and efficacy.
   

Thus, the aforementioned factor contributed to North America's dominance in the cell and gene therapy clinical trial services market.
 

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

• Germany has a particular focus on rare diseases and personalized medicine, areas where cell and gene therapies hold great promise. The country's Orphan Drug Act provides incentives for the development of therapies for rare diseases, including market exclusivity and fee reductions.
   
• Also, significant investments have been made in the country to build specialized infrastructure for cell and gene therapies research and development. This includes the establishment of advanced manufacturing facilities, research laboratories, and clinical trial centers dedicated to cell and gene therapy. Thus, the availability of technologically advanced infrastructure supports the expansion of cell & gene therapy clinical trial capabilities that drive the growth of the market.
   

India cell and gene therapy clinical trial services market is expected to grow with a significant CAGR during the forecast period.
 

• The presence of specialized research centers and clinical trial sites equipped with advanced facilities and trained personnel, supports the efficient execution of cell and gene therapy trials. Also, India's expanding network of research institutions and academic collaborations fosters innovation and expertise in areas relevant to cell and gene therapy research. Thus, the availability of research infrastructure, expertise and large patient pool drives demand for clinical trial services to support the development and execution of trials in India.
   

Cell and Gene Therapy Clinical Trial Services Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical & biotechnology companies along with CROs that collaborates to provide cell and gene therapy clinical trial services vying for market share. Key players are engaging in strategic initiatives such as collaboration, investment, and partnerships to strengthen their service portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for cell and gene therapy clinical trial services.
 

Cell and Gene Therapy Clinical Trial Services Market Companies

Prominent players operating in the cell and gene therapy clinical trial services industry are as mentioned below:

• ADVARRA
• Charles River Laboratories International Inc.
• Catalent Pharma
• ICON PLC
• IQVIA
• Medpace, Inc.
• Novotech
• Precision Medicine Group, LLC
• Parexel International
• Syneos Health
• Sharp Services, LLC
• Thermo Fisher Scientific Inc.
• Worldwide Clinical Trials
   

Cell and Gene Therapy Clinical Trial Services Industry News:

• In March 2024, Neurogene Inc. announced the expansion of its ongoing phase 1/2 gene therapy clinical trial for NGN-401 for female paediatric patients with Rett syndrome. This expansion of the clinical trial and the removal of staggered dosing in Cohort 1 enable the company to treat more patients in a shorter duration, thereby strengthening their pipeline products.
   
• In October 2023, eXmoor pharma launched its new Cell and Gene Therapy Centre good manufacturing practice (GMP) facility to support the production of multiple therapies for clinical trials. THe opening of this facility brings 19 years of translation consulting and process development experience to directly enable the rapid development of life changing therapies in the UK and other parts of regions. This strategy is expected to enhance their outreach to untapped economies.
   

The cell and gene therapy clinical trial services market research report include an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Service

• Clinical trial design & planning
• Supply & logistic services
• Regulatory affairs & compliance
• Data management & biostatics
• Site management & monitoring
• Other services

Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Market, By Indication

• Oncology
• Hematology
• Endocrine/metabolic disorders
• Infectious diseases
• Neurology
• Cardiovascular diseases
• Musculoskeletal disorders
• Other indications

Market, By Therapy Type

• Gene therapy
• Cell therapy
• Gene modified cell therapy  

Market, By End-Use

• Pharmaceutical & biotechnology companies
• Contract research organizations
• Academic & research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa